Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan

Summary

The primary objective is to determine if the use of losartan, an angiotensin II receptor blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive effects, in patients with near end stage chronic kidney disease (CKD) who have an arteriovenous fistula created. Secondary outcomes include the impact of the medication on BNP and hyperkalaemia

Timeline

Start

2006-10

Primary completion

2014-08

Completion

2014-12

Outcome

Missed primary endpoint

paper There was no difference in left ventricular mass between our groups 1-month post fistula creation. PMID 22642740 ↗

Publications

• Zentner D, Pedagogos E, Yapanis A, Karapanagiotidis S, Kinghorn A, Alexiou A, Lee G, Raspudic M, Aggarwal A. Can losartan and blood pressure control peri arteriovenous fistula creation ameliorate the early associated left ventricular hypertrophic response a randomised placebo controlled trial. BMC Res Notes. 2012 May 29;5:260. doi: 10.1186/1756-0500-5-260.

Drugs

Indications